Advances in immunotherapy for melanoma management

Dany, Mohammed; Nganga, Rose; Chidiac, Alissar; Hanna, Edith; Matar, Sara; Elston, Dirk M.

doi:10.1080/21645515.2016.1190889

Cited by 20 publications

(19 citation statements)

References 94 publications

(123 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this sense, immunotherapy emerges as a promising therapeutic option that involves therapeutic strategies with the common aim of enhancing the strengthens of the patient's immune system to advance upon tumors (4, 5). These systemic treatments for melanoma, approved or in experimental phase, include the administration of cytokines and other non-specific immunostimulatory molecules (IL-2, IFN-α2), active immunization (vaccination) with tumor cells, dendritic cells (DCs) or other molecules (recombinant antigens), adoptive transfer of T lymphocytes and monoclonal antibodies against immune checkpoint inhibitors (anti-CTLA-4, anti-PD1, anti-PDL1) (6).…”

Section: Introductionmentioning

confidence: 99%

Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

et al. 2019

View full text Add to dashboard Cite

The immune response against cancer generated by type-I-interferons (IFN-1) has recently been described. Exogenous and endogenous IFN-α/β have an important role in immune surveillance and control of tumor development. In addition, IFN-1s have recently emerged as novel DAMPs for the consecutive events connecting innate and adaptive immunity, and they also have been postulated as an essential requirement for induction of immunogenic cell death (ICD). In this context, photodynamic therapy (PDT) has been previously linked to the ICD. PDT consists in the administration of a photosensitizer (PS) and its activation by irradiation of the affected area with visible light producing excitation of the PS. This leads to the local generation of harmful reactive oxygen species (ROS) with limited or no systemic defects. In the current work, Me-ALA inducing PpIX (endogenous PS) was administrated to B16-OVA melanoma cells. PpIX preferentially localized in the endoplasmic reticulum (ER). Subsequent PpIX activation with visible light significantly induced oxidative ER-stress mediated-apoptotic cell death. Under these conditions, the present study was the first to report the in vitro upregulation of IFN-1 expression in response to photodynamic treatment in melanoma. This IFN-α/β transcripts upregulation was concurrent with IRF-3 phosphorylation at levels that efficiently activated STAT1 and increased ligand receptor (cGAS) and ISG (CXCL10, MX1, ISG15) expression. The IFN-1 pathway has been identified as a critical molecular pathway for the antitumor host immune response, more specifically for the dendritic cells (DCs) functions. In this sense, PDT-treated melanoma cells induced IFN-1-dependent phenotypic maturation of monocyte-derived dendritic cells (DCs) by enhancing co-stimulatory signals (CD80, MHC-II) and tumor-directed chemotaxis. Collectively, our findings showed a new effect of PDT-treated cancer cells by modulating the IFN-1 pathway and its impact on the activation of DCs, emphasizing the potential relevance of PDT in adoptive immunotherapy protocols.

show abstract

Section: Introductionmentioning

confidence: 99%

Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

et al. 2019

View full text Add to dashboard Cite

show abstract

“…An immune response can either repress tumor development and progression (for example, through immunosurveillance and the destruction of tumor cells) or promote it (for example, through secretion of protumorigenic and proinflammatory factors) ( 25 ). The prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in many cancer types ( 26 – 28 ) and the recent emergence of immunotherapy in clinical oncology ( 29 ) notably illustrate the importance of the immune system in cancer.…”

Section: Introductionmentioning

confidence: 99%

Immunity drives TET1 regulation in cancer through NF-κB

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Almost the totality of these pre-clinical studies has been performed immunizing mice and injecting subcutaneously or intravenously, in a preventive or curative setting, the B16 or B16-F10 melanoma cell lines. Thanks to successful studies performed in this pre-clinical model, several cancer vaccines have been tested, alone or in combination with CIs, in clinical trials [ 78 , 94 , 95 , 96 ].…”

Section: The Weakness Of Mouse Models: Testing Immunotherapy Againmentioning

confidence: 99%

Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy

Barutello

Rolih

Arigoni

et al. 2018

IJMS

View full text Add to dashboard Cite

Despite several therapeutic advances, malignant melanoma still remains a fatal disease for which novel and long-term curative treatments are needed. The successful development of innovative therapies strongly depends on the availability of appropriate pre-clinical models. For this purpose, several mouse models holding the promise to provide insight into molecular biology and clinical behavior of melanoma have been generated. The most relevant ones and their contribution for the advancement of therapeutic approaches for the treatment of human melanoma patients will be here summarized. However, as models, mice do not recapitulate all the features of human melanoma, thus their strengths and weaknesses need to be carefully identified and considered for the translation of the results into the human clinics. In this panorama, the concept of comparative oncology acquires a priceless value. The revolutionary importance of spontaneous canine melanoma as a translational model for the pre-clinical investigation of melanoma progression and treatment will be here discussed, with a special consideration to the development of innovative immunotherapeutic approaches.

show abstract

Advances in immunotherapy for melanoma management

Cited by 20 publications

References 94 publications

Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

Immunity drives TET1 regulation in cancer through NF-κB

Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy

Contact Info

Product

Resources

About